BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,079 filers reported holding BAXTER INTL INC in Q3 2019. The put-call ratio across all filers is 0.52 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $396,000 | -31.0% | 4,739 | -27.8% | 0.29% | -36.9% |
Q3 2019 | $574,000 | +2.3% | 6,564 | -4.2% | 0.46% | -2.7% |
Q2 2019 | $561,000 | +4.9% | 6,853 | +4.2% | 0.48% | +1.5% |
Q1 2019 | $535,000 | +36.8% | 6,579 | +10.7% | 0.47% | +13.3% |
Q4 2018 | $391,000 | -16.1% | 5,942 | -1.6% | 0.41% | -5.0% |
Q3 2018 | $466,000 | +3.6% | 6,041 | -0.8% | 0.44% | -4.8% |
Q2 2018 | $450,000 | +9.0% | 6,089 | -4.1% | 0.46% | +6.3% |
Q1 2018 | $413,000 | -3.5% | 6,347 | -4.1% | 0.43% | -0.7% |
Q4 2017 | $428,000 | – | 6,616 | – | 0.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |